3 Reasons Why Benda Pharmaceutical's Share Price Is Depressed
Aggregated Source: China Stocks News and Analysis from Seeking Alpha
November 29, 2007|
In its recent Q3 results, Benda Pharmaceutical (BPMA.OB) achieved impressive gains: sales were up 61% yoy,
while net income improved 50%. Indeed, most exciting of all, BPMA's
subsidiary SiBiono has made headlines as the only company in the world
to commercialize a gene therapy medicine for cancer, called Gendicine.
Original URL: Click here to visit original article
Copyright China Stocks News and Analysis from Seeking Alpha
Print This Post
|
Email This Page
Loading ...